Skip Navigation LinksHome > October 1, 2014 - Volume 67 - Issue 2 > The Effect of Tuberculosis Treatment on Virologic and Immuno...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0000000000000284
Clinical Science

The Effect of Tuberculosis Treatment on Virologic and Immunologic Response to Combination Antiretroviral Therapy Among South African Children

Soeters, Heidi M. PhD, MPH*; Sawry, Shobna MSc; Moultrie, Harry MBChB, MSc; Rie, Annelies Van MD, PhD*

Supplemental Author Material
Collapse Box


Background: Many HIV-infected children are diagnosed with tuberculosis (TB), but the effect of TB treatment on virologic and immunologic response to combination antiretroviral therapy (cART) is not well documented.

Methods: Secondary analysis of a prospective cohort of cART-naive HIV-infected South African children aged 0–8 years initiating cART to assess the effect of TB treatment at the time of cART initiation on virologic suppression (HIV RNA < 50 copies/mL), virologic rebound (HIV RNA > 1000 copies/mL after suppression), and CD4 cell percent (CD4%) increase during the first 24 months of cART.

Results: Of 199 children (median age 2.1 years), 92 (46%) were receiving TB treatment at cART initiation. Children receiving and not receiving TB treatment at cART initiation had similar median baseline HIV RNA (5.4 vs. 5.6 copies/mL), median time to virologic suppression (6.2 months in each group, adjusted hazard ratio, 1.36, 95% confidence interval: 0.94 to 1.96), and rates of virologic rebound by 24 months (23% vs. 24%, adjusted hazard ratio 1.53, 95% confidence interval: 0.71 to 3.30). Children on TB treatment had significantly lower median CD4% at baseline (15.3% vs. 18.8%, P < 0.01) and during the first 12 months of cART but experienced similar median increases in CD4% at 6 months (9.9% vs. 9.6%), 12 months (14.2% vs. 11.9%), and 24 months of cART (14.5% vs. 14.2%). Exploratory analyses suggest that children receiving lopinavir/ritonavir-based cART and TB treatment may have inferior virologic and immunologic response compared with children receiving efavirenz-based cART.

Conclusions: Receiving TB treatment at the time of cART initiation did not substantially affect virologic or immunologic response to cART in young children.

© 2014 by Lippincott Williams & Wilkins


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.